- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07759154
A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation
A Phase 3b, Multicenter, Open-label, Single-arm Trial to Evaluate the Efficacy and Safety of Orally Administered Centanafadine QD XR Capsules in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation
The primary purpose of this study is to evaluate the efficacy of centanafadine once daily (QD) extended-release (XR) capsules in adults with attention-deficit/hyperactivity disorder (ADHD) and emotional dysregulation (ED).
Studieöversikt
Status
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 3
Kontakter och platser
Studiekontakt
- Namn: Otsuka Call Center
- Telefonnummer: 844-687-8522
- E-post: otsuka-professionalservices@otsuka-us.com
Studieorter
-
-
Florida
-
Gainesville, Florida, Förenta staterna, 32607
- Rekrytering
- Sarkis Clinical Trials - Gainesville
-
Kontakt:
- Otsuka Call Center
- Telefonnummer: 844-687-8522
- E-post: Otsuka-ProfessionalServices@otsuka-us.com
-
Huvudutredare:
- Sarkis
-
Jacksonville, Florida, Förenta staterna, 32256
- Rekrytering
- CNS Healthcare - Jacksonville (Clinical Neuroscience Solutions - Jacksonville)
-
Huvudutredare:
- Jones
-
Kontakt:
- Otsuka Call Center
- Telefonnummer: 844-687-8522
- E-post: Otsuka-ProfessionalServices@otsuka-us.com
-
Maitland, Florida, Förenta staterna, 32751
- Rekrytering
- Accel Research Sites-Maitland
-
Kontakt:
- Otsuka Call Center
- Telefonnummer: 844-687-8522
- E-post: Otsuka-ProfessionalServices@otsuka-us.com
-
Huvudutredare:
- Marraffino
-
-
Louisiana
-
New Orleans, Louisiana, Förenta staterna, 70125
- Rekrytering
- Nola Research Works
-
Kontakt:
- Otsuka Call Center
- Telefonnummer: 844-687-8522
- E-post: Otsuka-ProfessionalServices@otsuka-us.com
-
Huvudutredare:
- Hebert
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02132
- Rekrytering
- Boston Clinical Trials
-
Kontakt:
- Otsuka Call Center
- Telefonnummer: 844-687-8522
- E-post: Otsuka-ProfessionalServices@otsuka-us.com
-
Huvudutredare:
- Mezhebovsky
-
Watertown, Massachusetts, Förenta staterna, 02472
- Rekrytering
- Adams Clinical - Watertown
-
Kontakt:
- Otsuka Call Center
- Telefonnummer: 844-687-8522
- E-post: Otsuka-ProfessionalServices@otsuka-us.com
-
Huvudutredare:
- Rutrick
-
-
Missouri
-
Saint Charles, Missouri, Förenta staterna, 63304
- Rekrytering
- St. Charles Psychiatric Associates/Midwest Research Group
-
Kontakt:
- Otsuka Call Center
- Telefonnummer: 844-687-8522
- E-post: Otsuka-ProfessionalServices@otsuka-us.com
-
Huvudutredare:
- Mattingly
-
-
Nevada
-
Las Vegas, Nevada, Förenta staterna, 89128
- Rekrytering
- Center for Psychiatry and Behavioral Medicine. Inc.
-
Kontakt:
- Otsuka Call Center
- Telefonnummer: 844-687-8522
- E-post: Otsuka-ProfessionalServices@otsuka-us.com
-
Huvudutredare:
- Childress
-
-
New Jersey
-
Cherry Hill, New Jersey, Förenta staterna, 08002
- Rekrytering
- Center for Emotional Fitness
-
Kontakt:
- Otsuka Call Center
- Telefonnummer: 844-687-8522
- E-post: Otsuka-ProfessionalServices@otsuka-us.com
-
Huvudutredare:
- Corcoran
-
-
New York
-
New York, New York, Förenta staterna, 10128
- Rekrytering
- The Medical Research Network, LLC
-
Kontakt:
- Otsuka Call Center
- Telefonnummer: 844-687-8522
- E-post: Otsuka-ProfessionalServices@otsuka-us.com
-
Huvudutredare:
- Careri
-
-
Ohio
-
Cincinnati, Ohio, Förenta staterna, 45215
- Rekrytering
- Patient Priority Clinical Trials
-
Kontakt:
- Otsuka Call Center
- Telefonnummer: 844-687-8522
- E-post: Otsuka-ProfessionalServices@otsuka-us.com
-
Huvudutredare:
- Popovitz
-
-
Oregon
-
Portland, Oregon, Förenta staterna, 97210
- Rekrytering
- Summit Research Network
-
Kontakt:
- Otsuka Call Center
- Telefonnummer: 844-687-8522
- E-post: Otsuka-ProfessionalServices@otsuka-us.com
-
Huvudutredare:
- Essink
-
-
Texas
-
Austin, Texas, Förenta staterna, 78737
- Rekrytering
- Donald J. Garcia, Jr, MD, PA
-
Huvudutredare:
- Garcia
-
Kontakt:
- Otsuka Call Center
- Telefonnummer: 844-687-8522
- E-post: Otsuka-ProfessionalServices@otsuka-us.com
-
Bellaire, Texas, Förenta staterna, 77401
- Rekrytering
- Houston Clinical Trials LLC
-
Kontakt:
- Otsuka Call Center
- Telefonnummer: 844-687-8522
- E-post: Otsuka-ProfessionalServices@otsuka-us.com
-
Huvudutredare:
- Katic
-
Houston, Texas, Förenta staterna, 77089
- Rekrytering
- Kaleidoscope Clinical Research
-
Kontakt:
- Otsuka Call Center
- Telefonnummer: 844-687-8522
- E-post: Otsuka-ProfessionalServices@otsuka-us.com
-
Huvudutredare:
- Higgins
-
-
Washington
-
Everett, Washington, Förenta staterna, 98201
- Rekrytering
- Core Clinical Research
-
Kontakt:
- Otsuka Call Center
- Telefonnummer: 844-687-8522
- E-post: Otsuka-ProfessionalServices@otsuka-us.com
-
Huvudutredare:
- Knutson
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria
- Primary diagnosis of ADHD per the Adult ADHD Clinical Diagnostic Scale (ACDS).
- Adult ADHD Investigator Symptom Rating Scale (AISRS) total score of ≥ 28 at baseline.
- Symptoms of ED as determined by the WRAADDS-ED subscale score ≥ 7 at baseline.
- CGI-S-ADHD rating ≥ 4 (at least moderate severity) at baseline.
Exclusion Criteria
- Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria for a lifetime diagnosis of bipolar and related disorders, schizophrenia spectrum and other psychotic disorders, borderline and antisocial personality disorders, neurocognitive disorders, autism spectrum disorder, or intellectual disability.
- DSM-5 criteria for a current diagnosis of major depressive disorder, post-traumatic stress disorder, any substance use disorder, untreated/unstable obstructive sleep apnea, eating disorders, or obsessive compulsive disorder.
- Any other current DSM-5 comorbid psychiatric disorder identified by the Mini International Neuropsychiatric Interview (MINI) or any medical condition that, in the judgment of the investigator, could be expected to require treatment with medications prohibited in this trial that cannot be safely discontinued with completion of an appropriate washout, could confound efficacy or safety assessments, or be the primary driver of ED.
- Presence of an unstable or uncontrolled medical condition that, in the opinion of the investigator, could pose a safety risk to the participant or could manifest with psychiatric symptoms (eg, thyroid disease).
- In the clinical opinion of the investigator, the participant has not derived significant therapeutic benefit from 2 or more ADHD therapies of 2 different classes (eg, amphetamine and methylphenidate, or amphetamine and atomoxetine) given with an acceptable dose and duration during adulthood (aged 18 years or older).
- Current use of prohibited psychotropic medications that cannot be discontinued within 7 to 28 days prior to enrollment.
- Any disorder that is the primary focus of treatment other than ADHD.
- Evidence of current substance use disorder or history in the past 12 months.
- History of any prior exposure to centanafadine.
- Participated in other clinical trials involving investigational drugs within 180 days prior to screening or participated in more than 2 interventional clinical trials involving investigational drugs within the past year.
- Have an allergy to the IMP or any component of the IMP.
Note: Other protocol-specified inclusion/exclusion criteria may apply.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Centanafadine XR
Participants will receive centanafadine XR capsule 328.8 milligrams (mg), orally, QD, for 8 weeks. |
Oral capsules
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Change From Baseline to Week 8 in the Wender-Reimherr Adult Attention Deficit Disorder Scale (WRAADDS) Total Score
Tidsram: Baseline up to Week 8
|
Baseline up to Week 8
|
Sekundära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Change From Baseline to Week 8 in the Wender-Reimherr Adult Attention Deficit Disorder Scale Emotional Dysregulation (WRAADDS-ED) Subscale Score
Tidsram: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Clinical Global Impressions-Severity Scale for Attention-Deficit/Hyperactivity Disorder (CGI-S-ADHD) Score
Tidsram: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Behavior Rating Inventory of Executive Function-Adult Version (BRIEF-A) T-score for the Global Executive Composite (GEC) Scale
Tidsram: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the BRIEF-A T-score for the Behavioral Regulation Index (BRI) Scale
Tidsram: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the BRIEF-A T-score for the Metacognition Index (MI) Scale
Tidsram: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Difficulties in Emotion Regulation Scale (DERS) Total Score
Tidsram: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Nonacceptance of Emotional Responses (NONACCEPT) DERS Subscale Score
Tidsram: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Difficulties Engaging in Goal-Directed Behavior (GOALS) DERS Subscale Score
Tidsram: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Impulse Control Difficulties (IMPULSE) DERS Subscale Score
Tidsram: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Lack of Emotional Awareness (AWARE) DERS Subscale Score
Tidsram: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Limited Access to Emotion Regulation Strategies (STRATEGIES) DERS Subscale Score
Tidsram: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Lack of Emotional Clarity (CLARITY) DERS Subscale Score
Tidsram: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Change From Baseline to Week 8 in the Attention-Deficit/Hyperactivity Disorder Symptoms, Executive Function Deficits, and Emotional Dyscontrol as Assessed by the Adult ADHD Self-Report Scale (ASRS) Score
Tidsram: Baseline up to Week 8
|
Baseline up to Week 8
|
|
Number of Participants With Adverse Events
Tidsram: Up to Week 9
|
Up to Week 9
|
|
Number of Participants With Suicidal Ideation or Behavior as Assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)
Tidsram: Up to Week 9
|
Up to Week 9
|
Samarbetspartners och utredare
Publikationer och användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 405-201-00231
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Anonymized individual participant data (IPD) that underlie the results of this study will be shared with researchers to achieve aims pre-specified in a methodologically sound research proposal. Small studies with less than 25 participants are excluded from data sharing.
Tidsram för IPD-delning
Data will be available after marketing approval in global markets, or beginning 1-3 years following article publication. There is no end date to the availability of the data.
Kriterier för IPD Sharing Access
Otsuka will share data on the Vivli data sharing platform: https://vivli.org/ourmember/Otsuka/
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
- SAV
- ICF
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .